VolitionRx Limited (VNRX)
| Previous Close | 0.8660 |
| Open | 0.9000 |
| Bid | 0.8710 x 800 |
| Ask | 0.8891 x 900 |
| Day's Range | 0.8710 - 0.9112 |
| 52 Week Range | 0.5500 - 2.0900 |
| Volume | |
| Avg. Volume | 188,816 |
| Market Cap | 72.59M |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech, a leading veterinary diagnostics company.
- PR Newswire
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year ended December 31, 2023. Volition management will host a conference call tomorrow, March 26 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.
- PR Newswire
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 26 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full year 2023, in addition to providing a business update. Details of this event can also be found below.
